OncoSec Medical Incorporated · OTC:ONCSQ
OncoSec Medical — Investor Presentation (September 2020)
28 slides from OncoSec Medical's investor presentation, September 2020
Slide 1: Powerful, Tumor-agnostic Immunotherapy Treatment
Powerful, Tumor-agnostic Immunotherapy Treatment ONCOSEC’S PLATFORM TO ATTACK VISCERAL, CUTANEOUS AND SUBCUTANEOUS TUMORS NASDAQ: ONCS SEPTEMBER 2020
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS To the extent statements contained in the following retain key scientific or management personnel; (viii) the presentations are not descriptions of historical facts anticipated timing of clinical data availability; (ix) the regarding OncoSec Medical Incorporated, they shou
Slide 3: OncoSec at a Glance
OncoSec at a Glance We are a late-stage biotechnology company focused on intratumoral DNA based immunotherapies. • Headquarters: Pennington, NJ, with R&D Laboratories in San Diego, CA • Ticker: NASDAQ: ONCS • Market Cap (as of 7/20/20): ~$82M • Stock Price (as of 7/20/20): $3.57 Technology: Our lead
Slide 4: The Promise of Immunotherapy Has Yet to Be Fully Realized
The Promise of How Checkpoint Inhibitors Work Immunotherapy Has Yet 1 Molecular switches known as to Be Fully Realized checkpoints normally prevent T-cells from attacking healthy tissue When these checkpoints, such as PD-1 2 and PD-L1, are hijacked by cancer cells, the immune system’s T-cell respons
Slide 5: Checkpoint Non-response in 60-90% of Cases
Checkpoint Powerful drugs (like KEYTRUDA®) have been highly Non-response successful for some patients, but not the majority in 60-90% 90% of cancers are solid tumors. Of these: of Cases % OF CHECKPOINT TUMOR TYPE NON-RESPONDERS MELANOMA ˜60-80% ~30% ~70% Hot Tumors Cold Tumors TRIPLE NEGATIVE BREAST
Slide 6: TAVO is Capable of Reversing Resistance to Checkpoint Therapies
TAVO (plasmid-based interleukin-12) is administered locally TAVO™ is Capable of at the tumor site using OncoSec’s electroporation gene delivery system. TAVO is designed to induce local Reversing Resistance expression of IL-12, turning “cold” tumors “hot” and enabling checkpoint therapies to be effec
Slide 7: Benefits of Electroporation (EP) Gene Delivery System
Benefits of Electroporation (EP) Gene Delivery System Rapid Transfection Versatile More rapid than Wide array of molecules can A non-invasive, traditional chemical or biologic cell transfection be transfected, and can be applied to a broad selection non-chemical, techniques of cell types non-toxic m
Slide 8: Seamless Delivery of Plasmid IL-12 + Energy
Seamless Delivery of Plasmid IL-12 + Energy Step 1: TAVO™ Injection Multiple copies of IL-12 coded DNA plasmids to produce immune modulatory proteins are injected directly into the tumor using a conventional needle and syringe. Step 2: Applicator Insertion The applicator’s tip needle array is insert
Slide 9: TAVO: A Tumor Agnostic Platform with Single Agent Activity
5 TAVO: A Tumor Agnostic CLINICAL/ IMMUNOLOGICAL Platform with Single Agent SIGNAL IN FIVE TUMOR TYPES Activity TAVO + PEMBRO COMBINATION TAVO SINGLE AGENT SPONSORED TRIALS INVESTIGATOR-SPONSORED TRIALS Metastatic Melanoma Metastatic TNBC U.S. Orphan Accelerated Approval Fast Track Metastatic Metast
Slide 10: Clinical Pipeline is Well Diversified with Multiple Growth Opportunities
Clinical Pipeline is Well Diversified with Multiple Growth Opportunities REGIMEN TRIAL INDICATION N PARTNER PHASE 1 PHASE 2 PIVOTAL Checkpoint TAVO + KEYNOTE-695 Resistant Metastatic ~100 pembrolizumab Melanoma Triple Negative TAVO + KEYNOTE-890 Breast Cancer ~65 pembrolizumab (TNBC) TAVO™ TAVO + Sq
Slide 11: Recent Peer Reviewed Publications
Recent Peer Reviewed Publications *Click thumbnails to access full articles TAVO + PEMBRO IN ANTICIPATED TAVO SINGLE AGENT ABSCOPAL EFFECT ANTI-PD-1 CHECKPOINT FAILURES 11
Slide 12: FDA Fast Track KEYNOTE-695
FDA Fast Track KEYNOTE-695 Ongoing pivotal trial in PD-1 checkpoint resistant metastatic melanoma provides a pathway towards accelerated approval GRANTED FAST TRACK AND ORPHAN DRUG DESIGNATIONS Fast-track makes Program for patients Must meet TAVO™ eligible for with no FDA RECIST (tumor accelerated a
Slide 13: KEYNOTE-695 Trial Design and Eligibility
Up To Number Of 30 Sites PATIENTS TO BE TREATED 100 Canada Italy United States Australia DEFINITIVE CLINICAL PROGRESSION ON FULL COURSE ANTI-PD-1 Stage 3/4 Received at Progressive Documented No intervening Eligible Melanoma therapies permitted patient/definitive least 12 weeks + disease + disease +
Slide 14: Metastatic Melanoma
P R E L I M I N A R Y D ATA KEYNOTE-695 STUDY EVALUATING Metastatic Melanoma 100 PATIENTS - ONGOING TAVO™ + KEYTRUDA® (pembrolizumab) for Checkpoint Refractory Metastatic/Recurrent Melanoma 4 PRs and 1 CR out Durable responses Responders are Responders of 21 patients observed patients with bulky dem
Slide 15: US Market Opportunity
US Market Focusing First on Metastatic Melanoma Opportunity in the United States 91,000 diagnosis 9,000 deaths each year each year 90% of all cancer cases are solid tumors Incidence of melanoma US melanoma market on the projected to almost 1.6M new cases of solid tumors in the US rise (1.4% yearly f
Slide 16: Commercialization by 2022 Targeted
Commercialization by 2022 Targeted 2020 2022 Pre-BLA Meeting FDA Accelerated Approval of TAVO with FDA for Metastatic Melanoma Potential US TAVO is US Orphan Designated and Keynote-695 is fast Regulatory 2021 tracked. OncoSec will seek Timeline Submission of BLA for accelerated approval Accelerated
Slide 17: Expanding KEYNOTE-890 into First-Line mTNBC
Expanding KEYNOTE-890 into First-Line mTNBC Primary Endpoint: ORR by blinded independent central PHASE 2 COHORT 1 COHORT 2 review (BICR) based Multi-cohort, open-label study TAVO and KEYTRUDA TAVO and KEYTRUDA plus on RECIST v1.1 of TAVO in combination with in patients with heavily Chemotherapy in p
Slide 18: TAVO is Tumor Agnostic: Future Opportunities
FUTURE OPPORTUNITIES TAVO™ is Tumor Agnostic Renal Cell Ovarian Head/Neck Carcinoma Triple Negative Bladder Colorectal Giving life to the promise of Pancreatic Breast immunotherapies across cancer types HI Few cancers are highly infiltrated or “HOT” - most LYMPHOCYTES fall on a spectrum from warm (c
Slide 19: The Power of TAVO for Visceral Lesions
The Power of TAVO™ INTRODUCING THE for Visceral Lesions VLA: Visceral Lesion Applicator (liver, GI, lung) Pioneering technology designed to target and treat Flexible catheter- based applicator Rigid trocar-based applicator tumors located deep inside the body Lower voltage Apollo generator to be used
Slide 20: VLA Highlights
VLA Highlights Rigid and catheter models: 1 Used with bronchoscope, cystoscope, and trocar Prototype successfully tested in 2 large animal model: bone, pancreas, liver, lung, & bladder NEEDLE/ELECTRODES EXPANDED ELECTROPORATION ENTERS THE ORGAN DRUG DELIVERY OCCURS 1 2 3 20
Slide 21: CORVax12 Vaccine for COVID-19
CORVax12 Vaccine for COVID-19 CORVax12 is a DNA vaccine The combination of IL-12 and Providence Cancer Institute to which combines OncoSec’s NIH’s spike protein is designed conduct Phase I trial of CORVax12 TAVO / IL-12 immunotherapy to drive a coordinated vaccine – Providence submitted with NIH’s “
Slide 22: Leveraging World Class Strategic Partnerships to Enhance Pipeline Value
Leveraging World Class Strategic Partnerships to Enhance Pipeline Value We are partnering with Merck Emerge collaboration provides Our partnership with CGP gives Through our partnership with on several KEYNOTE clinical Australian metastatic us the ability to develop and Sirtex, we have access to top
Slide 23: Strong Financial Position to Drive TAVO Development Forward
Strong Financial Position to Drive TAVO™ Development Forward $30.1M 27,771,571 Cash & Equivalent as of Total Shares Outstanding 4/30/20 as of 8/31/20 ~$14M Financing Completed August 2020 None Debt 23
Slide 24: Key Developments in 1H 2020
Key Developments in 1H 2020 Closed on $30 million strategic financing and partnership with CGP/Sirtex Presented promising preclinical data on novel visceral lesion applicator Announced partnership with Providence Cancer Institute to investigate OncoSec’s CORVax-12 vaccine for COVID-19 Appointed reno
Slide 25: Anticipated Milestones
Anticipated Milestones Provide interim data update at SITC 2020 for KEYNOTE-695 Complete enrollment in pivotal KEYNOTE-695 study Prepare to file TAVO™ for accelerated FDA approval in metastatic melanoma Initiate TAVO neoadjuvant study in metastatic melanoma Complete preclinical assessment and IND pr
Slide 26: Established Biotech Leaders
BOARD OF DIRECTORS Established Biotech Leaders Daniel J. O’Connor, JD WITH A TRACK RECORD OF SUCCESS Chief Executive Officer & Director Margaret R. Dalesandro, Ph.D. Chair MANAGEMENT Herbert Kim Lyerly, M.D. Director Daniel J. O’Connor Kellie Malloy Foerter Chao Zhou President/Director/CEO Chief Ope
Slide 27: OncoSec is Positioned for Success with TAVO
OncoSec is Positioned Positive tumor Well tolerated, natural shrinkage/response data being solution that may increase generated by our lead product the efficacy of checkpoint for Success with candidate, TAVO, across multiple solid tumor types therapies TAVO™ Expanding device Fast track status and de
Slide 28: Thank You
Thank You Keir Loiacono HEAD OF CORPORATE DEVELOPMENT 914.329.9071 kloiacono@oncosec.com HEADQUARTERS SCIENTIFIC LAB & RESEARCH 24 NORTH MAIN STREET 3565 GENERAL ATOMICS CT. PENNINGTON, NJ SAN DIEGO, CA
OncoSec Medical — Investor Presentation (September 2020) on 6ix